Yellow header pointerResults with TECVAYLI®

TECVAYLI® was studied in 110 adults, 78% of whom had already been on at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

People icon

TECVAYLI® was studied in 110 heavily pretreated patients:

All patients have previously received a proteasome inhibitor, an immunomodulatory agent, and an anti- monoclonal antibody:

green bullet icon

At least half of the patients had received 5 prior treatment regimens


green bullet icon

78% of patients had 4 prior treatment regimens


62% responded to TECVAYLI® (teclistamab-cqyv)62% responded to TECVAYLI® (teclistamab-cqyv)

experienced or better

experienced
a

experienced a

experienced
a

to treatment

experienced a
to treatment

62%

62% of people who took TECVAYLI® responded.

1 month calendar icon

Median time to first response with TECVAYLI® was 1.2 months (response times ranged from 0.2 months to 5.5 months).

Register to stay up-to-date with important information about TECVAYLI®